fosravuconazole
Small moleculeexperimental
Fosravuconazole is a triazole antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2017 (NCT03086226)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cytochrome P450 51INHIBITOR
ERG11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F- Mol. weight
- 547.48 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFosravuconazole ↗
- ChEMBLCHEMBL333325 ↗
Also known as
- fosravuconazole
- fosravuconazole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03086226 | Phase 2 | Apr 30, 2017 | Drugs for Neglected Diseases Initiative, Soba University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Drugs for Neglected Diseases Initiative | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Soba University | Academic/Hospital | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1